Find trials
Search tips

Prevalence Of MIC A Antibodies In T1D

Overview

About this study

The purpose of this study is to evaluate the prevalence of MIC A antibodies in adult participants with T1D

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Adults (aged 18 to 65 years, inclusive)

  • Known history of T1D, including:

    • Onset of T1D at <40 years of age

    • Insulin dependence for ≥5 years at time of signing ICF

  • Provide voluntary written consent before performance of any study-related procedures

  • Willingness and ability to comply with study procedures

Exclusion Criteria:

  • Any condition that precludes safe blood collection (e.g., bleeding disorder, severe anemia, poor venous access)

  • Any factor that, in the Investigator judgement, makes participation inappropriate

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 06/15/2026. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Yogish Kudva, M.B.B.S.

Contact us for the latest status

Contact information:

Chloe Miller

5072550316

miller.chloe4@mayo.edu

More information

Publications

Publications are currently not available

More about research at Mayo Clinic

.
CLS-20604167

Mayo Clinic Footer